Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
03 June 2022 - 6:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022
Commission File Number 001-40617
Regencell Bioscience Holdings Limited
11/F First Commercial Building
33-35 Leighton Road
Causeway Bay, Hong Kong
(Address of principal executive office)
Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Pursuant to Nasdaq Rule 5250(c)(2), Regencell
Bioscience Holdings Limited (the “Company”) hereby furnishes its interim balance sheet and statement of operations for its
six months ended on December 31, 2021, which are attached as Exhibit 99.1 to this Form 6-K.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: June 2, 2022 |
|
|
| |
|
|
| |
Regencell Bioscience Holdings Limited |
| |
|
|
| |
By: |
/s/ Yat-Gai Au |
| |
|
Name: Yat-Gai Au |
| |
|
Title: Chief Executive Officer and
Chairman of the Board of Directors |
2
Regencell Bioscience (NASDAQ:RGC)
Historical Stock Chart
From May 2024 to Jun 2024
Regencell Bioscience (NASDAQ:RGC)
Historical Stock Chart
From Jun 2023 to Jun 2024
